Novartis Gleevec Will Be First-Line Therapy For Early CML At M.D. Anderson
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
University of Texas’ M.D. Anderson Cancer Center will use the signal transduction inhibitor Gleevec as first-line treatment for chronic myeloid leukemia (CML) in the chronic, or early, phase, Hagop Kantarjian, MD, acting chair of M.D. Anderson’s Department of Leukemia, told a May 11 educational symposium at the American Society of Clinical Oncology annual meeting.